(Alliance News) - Laboratorio Farmaceutico Erfo Spa reported Wednesday evening that its board of directors reviewed some consolidated economic and financial operating data as of March 31, 2024, reporting revenues of EUR1.50 million, in line with EUR1.48 million in the same period a year earlier.

Adjusted Ebitda is EUR320,000 from EUR370,000 in Q1 2023, with an Ebitda margin of 22 percent from 25 percent in the same period 2023.

The company emphasized the decision "to concentrate a large part of the advertising budget in the period preceding the months when revenues are historically highest - second quarter - as well as to strengthen the logistics, commercial and R&D structure."

Net financial position is cash positive at EUR1.95 million from EUR1.72 million on Dec. 31.

Laboratorio Farmaceutico Erfo's stock closed Wednesday in the green by 3.3 percent at EUR1.24 per share.

By Chiara Bruschi, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2024 Alliance News IS Italian Service Ltd. All rights reserved.